The Prometheus League
Breaking News and Updates
- Abolition Of Work
- Ai
- Alt-right
- Alternative Medicine
- Antifa
- Artificial General Intelligence
- Artificial Intelligence
- Artificial Super Intelligence
- Ascension
- Astronomy
- Atheism
- Atheist
- Atlas Shrugged
- Automation
- Ayn Rand
- Bahamas
- Bankruptcy
- Basic Income Guarantee
- Big Tech
- Bitcoin
- Black Lives Matter
- Blackjack
- Boca Chica Texas
- Brexit
- Caribbean
- Casino
- Casino Affiliate
- Cbd Oil
- Censorship
- Cf
- Chess Engines
- Childfree
- Cloning
- Cloud Computing
- Conscious Evolution
- Corona Virus
- Cosmic Heaven
- Covid-19
- Cryonics
- Cryptocurrency
- Cyberpunk
- Darwinism
- Democrat
- Designer Babies
- DNA
- Donald Trump
- Eczema
- Elon Musk
- Entheogens
- Ethical Egoism
- Eugenic Concepts
- Eugenics
- Euthanasia
- Evolution
- Extropian
- Extropianism
- Extropy
- Fake News
- Federalism
- Federalist
- Fifth Amendment
- Fifth Amendment
- Financial Independence
- First Amendment
- Fiscal Freedom
- Food Supplements
- Fourth Amendment
- Fourth Amendment
- Free Speech
- Freedom
- Freedom of Speech
- Futurism
- Futurist
- Gambling
- Gene Medicine
- Genetic Engineering
- Genome
- Germ Warfare
- Golden Rule
- Government Oppression
- Hedonism
- High Seas
- History
- Hubble Telescope
- Human Genetic Engineering
- Human Genetics
- Human Immortality
- Human Longevity
- Illuminati
- Immortality
- Immortality Medicine
- Intentional Communities
- Jacinda Ardern
- Jitsi
- Jordan Peterson
- Las Vegas
- Liberal
- Libertarian
- Libertarianism
- Liberty
- Life Extension
- Macau
- Marie Byrd Land
- Mars
- Mars Colonization
- Mars Colony
- Memetics
- Micronations
- Mind Uploading
- Minerva Reefs
- Modern Satanism
- Moon Colonization
- Nanotech
- National Vanguard
- NATO
- Neo-eugenics
- Neurohacking
- Neurotechnology
- New Utopia
- New Zealand
- Nihilism
- Nootropics
- NSA
- Oceania
- Offshore
- Olympics
- Online Casino
- Online Gambling
- Pantheism
- Personal Empowerment
- Poker
- Political Correctness
- Politically Incorrect
- Polygamy
- Populism
- Post Human
- Post Humanism
- Posthuman
- Posthumanism
- Private Islands
- Progress
- Proud Boys
- Psoriasis
- Psychedelics
- Putin
- Quantum Computing
- Quantum Physics
- Rationalism
- Republican
- Resource Based Economy
- Robotics
- Rockall
- Ron Paul
- Roulette
- Russia
- Sealand
- Seasteading
- Second Amendment
- Second Amendment
- Seychelles
- Singularitarianism
- Singularity
- Socio-economic Collapse
- Space Exploration
- Space Station
- Space Travel
- Spacex
- Sports Betting
- Sportsbook
- Superintelligence
- Survivalism
- Talmud
- Technology
- Teilhard De Charden
- Terraforming Mars
- The Singularity
- Tms
- Tor Browser
- Trance
- Transhuman
- Transhuman News
- Transhumanism
- Transhumanist
- Transtopian
- Transtopianism
- Ukraine
- Uncategorized
- Vaping
- Victimless Crimes
- Virtual Reality
- Wage Slavery
- War On Drugs
- Waveland
- Ww3
- Yahoo
- Zeitgeist Movement
-
Prometheism
-
Forbidden Fruit
-
The Evolutionary Perspective
Category Archives: Transhuman News
Read this: 25 years ago, Chumbawamba smuggled anarchist ideals onto the U.S. pop charts – The A.V. Club
Posted: January 28, 2022 at 12:10 am
ChumbawambaScreenshot: Chumbawamba
Everyone remembers where they were when they learned that Chumbawamba was more than a 90s one-hit-wonder and actually a long-running anarcho-communist punk band with a loyal following in jolly ol England; it may even be happening to you right now! Mel Magazine is marking the 25th anniversary of 1997 and wrote about the alcohol-propelled Trojan horse that was Tubthumping, a song that brought the bands subversive politics to the top of the Billboard Alternative charts and provided the pop culture zeitgeist with one of the most memorable choruses of the decade.
Its a rock n roll tale as old as time: a band that has been working at it for years decides their next album needs to be hit theyve been searching for or theyre packing it in. And then, through the grace of A&Ror maybe just luckthey finally score the chartbuster of their career with a tune that steps outside of their comfort zone and might even alienate their long-time fans.
Chumbawamba had experimented in punk, ska, folk, and electronica, but Tubthumping was pure pop from the songwriting to the production with horns, hooks, and an anthemic chorus quite literally meant to be sung at the top of your lungs in a crowded bar. But underneath the surface, the band remained true to its roots with lyrics conveying a deeper message of the workers surviving the daily grind as explained by band member Alice Nutter to CNN 1997. Tubthumping would debut at #2 on the UK Singles Chart in August of 1997 and would overtake the states over the following months, hitting #6 on the Billboard Hot 100 that November.
We decided to use the situation to our own ends. At that time, we thought, What can we do with this, explains lead vocalist Dunstan Bruce. The song itself is evidence of the fact that if you can find ways to invade your way into cultureyou can use that as a kind of smokescreen to say the other stuff that you want to say.
Chumbawamba did just that, like a merry gang of anarchist pranksters, they weaponized their success to bring to light their political and social beliefs and take on major corporations through the power of pop music.
The band replaced the lyrics of Tubthumping to Free Mumia Abu-Jamal on a Late Show performance, encouraged people to steal their album from Virgin Megastores on Politically Incorrect, and (this writers personal favorite) allowed General Motors to play a song of theirs in a car commercial and then donated all their profits to anti-GM groups. They were incredibly subversive, but they also were trolls, explains Chumbawamba enthusiast and Eve 6 singer, Max Collins. Not all trolls are bad.
Chumbawamba called it quits in 2012, performing their final show at Leeds City Varieties on Halloween night and Bruce is currently in production on a documentary on the band due out later this year.
These days, countless copies of Tubthumper line used CD stores across the country while the real message of Tubthumping is still lost on nostalgic 40-somethings on their fifth or sixth whiskey drink, vodka drink, lager drink, or cider drink.
[via Mel Magazine]
Posted in Politically Incorrect
Comments Off on Read this: 25 years ago, Chumbawamba smuggled anarchist ideals onto the U.S. pop charts – The A.V. Club
Now Playing: Friday, January 28, through Thursday, February 3 – River Cities Reader
Posted: at 12:10 am
Davenport 53rd 18 + IMAX,Davenport IA
FilmScene,Iowa City IA
Marcus Sycamore Cinema,Iowa City IA
Putnam Museum & Science Center, Davenport IA
Regal Moline,Moline IL
(Hyperlinked titles take you to Readerreviews; IMDb hyperlinks take you to the films Internet Movie Database pages.)
***
The 355(PG-13; Davenport 53rd 18 + IMAX, Regal Moline, Marcus Sycamore Cinema)- Even though Simon Kinberg's direction is resolutely bland, and even though his and Theresa Rebeck's screenplay is perfunctory at best and groan-worthy at worst, it's not at all difficult to enjoy yourself at this hodgepodge tale of espionage, betrayal, and hastily procured designer gowns.IMDb listing.
American Underdog(PG; Davenport 53rd 18 + IMAX, Regal Moline, Marcus Sycamore Cinema)- While this football bio-picmight not offer much in the way of narrative surprise, especially if you're familiar with the Kurt Warner legend, it makes up for its formulaic predictability with sincerity and endearing performances.IMDb listing.
Back from the Brink: Saved from Extinction(not rated; Putnam Museum & Science Center)- This edu-docwould be recommended solely for the chance, for 40 minutes, to actually feel momentarily great about the state of the human race.IMDb listing.
Crypt of the Living Dead(R; FilmScene at the Chauncey: Wednesday, February 2, 10 p.m.)- IMDb listing.
The Film Lounge 2022 (not rated; FilmScene at the Chauncey: Saturday, January 29, 12:30 p.m.)- IMDb listing.
Flee(PG-13; FilmScene at the Chauncey)- IMDb listing.
Ghostbusters: Afterlife(PG-13; Davenport 53rd 18 + IMAX, Regal Moline)- It would be wonderful to report that Jason Reitman's sequel to his dad's comedy classic was nothing more, or less, than goofy dumb fun. But if you only smile four times (I counted) over the course of two hours, I'm not sure that qualifies as having fun.IMDb listing.
Good Luck Sakhi(not rated; Davenport 53rd 18 + IMAX)- IMDb listing.
House of Gucci(R; Regal Moline)-Lady Gaga is abona fidemovie star, but while her electric spark and charisma keep you invested, enjoying the diva's routines here also means putting up withso much else.IMDb listing.
In Bruges(R; FilmScene at the Chauncey: Saturday, February 29, 10 p.m.)-Martin McDonagh's first, still-finest feature film casts Brendan Gleeson and Golden Globe winner Colin Farrell as chatty Irish hit men in a film that's profane, bloody, politically incorrect, horrifying, and hilarious.IMDb listing.
Into America's Wild(not rated; Putnam Museum & Science Center)- IMDb listing.
Introduction(not rated; FilmScene at the Chauncey)- IMDb listing.
The King's Daughter(PG; Davenport 53rd 18 + IMAX, Regal Moline, Marcus Sycamore Cinema)-You kind of know what you're in for from the start of this deeply uninteresting fantasy adventure,with Julie Andrews' gentle, mellifluous narration guaranteeing an experience that'll be indistinguishable from a nap.IMDb listing.
The King's Man(R; Davenport 53rd 18 + IMAX, Regal Moline)- Despite Ralph Fiennes' heroic work, this is a prequel that involves Grigori Rasputin, Mata Hari, and a one-minute role for Stanley Tucci that still manages to be almost no fun at all.IMDb listing.
Lenny Cooke(not rated; FilmScene at the Chauncey: Tuesday, February 1, 7 p.m.)- IMDb listing.
Licorice Pizza(R; FilmScene on the Ped Mal)- Paul Thomas Anderson's latest is like the movie version of a chocolate-covered pretzel: saltyandsweet, and something that, once consumed, makes you instantly crave more.IMDb listing.
Love & Basketball(PG-13; Marcus Sycamore Cinema: Thursday, February 3, 7:05 p.m.)- IMDb listing.
The Matrix Resurrections(R; Marcus Sycamore Cinema)-Massively produced and modestly winning, this sci-fi sequel is also deeply unnecessary yet unexpectedly charming, and should ensure that the red pill/blue pill debate continues at least until we enter these particular realms again.IMDb listing.
The Met:Rigoletto(not rated; Davenport 53rd 18 + IMAX, Marcus Sycamore Cinema: Saturday, January 29, 11:55 a.m.)- FathomEvents.com.
Moonfall: Advance Screenings (PG-13; Marcus Sycamore Cinema: Saturday, January 29, and Sunday, January 30, 7 p.m.)- IMDb listing.
Nightmare Alley: Vision in Darkness & Light(R; Davenport 53rd 18 + IMAX, Marcus Sycamore Cinema)- A black-and-white version of this gorgeously designed noirin which Guillermo del Toro's lethargic pacing and unusually drab compositions dull your interest in even the actors' expert contributions.IMDb listing.
Oceans(G; Putnam Museum & Science Center)- This edu-doc is a little bland, butit's hard to be too disappointed by a film that provides so many extraordinary sights.IMDb listing.
On These Grounds(not rated; FilmScene at the Chauncey: Thursday, February 3, 6:30 p.m.)- IMDb listing.
Parallel Mothers(R; FilmScene at the Chauncey)- IMDb listing.
Redeeming Love(PG-13; Davenport 53rd 18 + IMAX, Regal Moline)- This earnest, tacky, largely offensive trifle is, thanks to a handful of unexpectedly resonant performances, a lot less icky than it should have been.IMDb listing.
Scream(R; Davenport 53rd 18 + IMAX, Regal Moline, Marcus Sycamore Cinema)- While this latest, incessantly meta horror-comedy sequelis frequently clever and easily watchable, it also kept reminding me, unfortunately, that there's a fine line between smart and smarty-pants.IMDb listing.
Shang-Chi & the Legend of the Ten Rings(PG-13; Marcus Sycamore Cinema)- It's stuck with a formulaic storyline and emotional banality, but this Marvel adventure at least boasts a bevy of terrifically sharp and well-choreographed set pieces that are bound to stick in memory.IMDb listing.
Sing 2(PG; Davenport 53rd 18 + IMAX, Regal Moline, Marcus Sycamore Cinema)- TheAlice in Wonderlandopener delivers a jazzy re-introduction to writer/director Garth Jennings' show-biz wannabes, whose new film is understandably less inventive, but decidedly more satisfying, than its 2016 predecessor.IMDb listing.
Spider-Man: No Way Home(PG-13; Davenport 53rd 18 + IMAX, Regal Moline, Marcus Sycamore Cinema)- Jon Watts' third showcase for Tom Holland's Spider-Man is an initially dreary, ultimately exhilarating love letter to Marvel fans.IMDb listing.
Superpower Dogs(G; Putnam Museum & Science Center)-Writer/director Daniel Ferguson provides enough globe-trotting action for a James Bond flick, and we're given just enough information on how the heroic pups pull off their feats of derring-do to wholly appreciate them in practice.IMDb listing.
The Tiger Rising(PG; Davenport 53rd 18 + IMAX)- IMDb listing.
Titans of the Ice Age(not rated; Putnam Museum & Science Center)- Gorgeously photographed and boasting perhaps the finest CGI I've ever seen in aNational Geographicdoc, the film is both informative and a heck of a lot of fun.IMDb listing.
The Tragedy of Macbeth(R; FilmScene on the Ped Mall)- In perhaps a first for my personal acquaintance with this much-cherished Shakespeare saga, I didn't feel anything aside from respect for its designers while watching it.IMDb listing.
The Velvet Queen(not rated; FilmScene on the Ped Mall)- IMDb listing.
Venom:Let There Be Carnage(PG-13; Regal Moline)- At least it's not the 2018Venom, meaning that this one occasionallydoesn'tsuck.IMDb listing.
West Side Story(PG-13; Regal Moline, Marcus Sycamore Cinema)- Happily, and gratefully, Steven Spielberg's musical remakeis a film clearly made by people who both adore its 60-year-old predecessor and still saw 21st-century room for improvement.IMDb listing.
Wild Africa(not rated; Putnam Museum & Science Center)- IMDb listing.
Go here to read the rest:
Now Playing: Friday, January 28, through Thursday, February 3 - River Cities Reader
Posted in Politically Incorrect
Comments Off on Now Playing: Friday, January 28, through Thursday, February 3 – River Cities Reader
Twitter Bans Wordlinator, A Bot that Spoils the Wordle Game in the Social Media – Tech Times
Posted: at 12:10 am
A Twitter bot now faces a ban on social media because of the many spoilers and wreaking havoc by giving the next word of the day. The bot called "Wordlinator" faces prohibition as it afflicts many users that post their Wordle scores online. The bot will reply to the score tweet and tell the person the next word of the day right then and there.
(Photo : Image from Joshua Hoehne on Unsplash)Twitter Tests iOS App Search Bar on Its Home Tab
According to areportby The Verge, the social media company of Twitter already banned the bot in the platform called "Wordlinator" with the handle "@wordlinator." The bot is known for its "killjoy" attitude that gives away the answer for the next word of the day in the said game, defeating the purpose of those that wants to play.
ATwitter user also shows what the botdoes in certain situations, and it would most likely appear when one tweets about anything related to Wordle and its game scores. Here, the next day's word to be the game's focus will get spoiled by the bot, affecting the experience of many.
Read Also:Elon Musk Bashes Twitter's New NFT Profile Feature-Saying Platform Wastes Engineering Resources
Worldlinator is a bot on Twitter, and it was made by a user that comes as an account but doubles as an algorithm or program that scans the social media for Wordle scores mentioned. The bot would then tweet the users and reveal the next day's word.
The bot also degrades the user by picking on their scores.
Twitter bots are popular in the social media landscape, and this is because people are fond of them as they immediately pop on your replies when a specific keyword gets publicized. Tweeting online sure does have lots of lurkers to see and inspect one's profile, even bots that run around millions of tweets per day, looking for their opportunity to reply to tweets.
One popular Twitter bot was something that raised awareness on the term called"illegal immigrants," where advocatespushed that it is a "politically incorrect" term for those people. Here, the bot would correct them and let them know that they misused the time, especially as it brings discrimination to addressing the minorities.
Another popular bot is the one called "COVAX SF," which was particularly helpful during the first stages of the vaccination campaign of the country. Before, doses and schedules were complicated and challenging.
Twitter bots are like the bots from Discord, Reddit, Telegram, and other online platforms that allow people to enjoy the experience or see more of different offers within the app.
However, if it spoils the experience, it has to go.
Related Article:Twitter NFT Profile Picture Releases to Twitter Blue Subscribers | How it Works
This article is owned by Tech Times
Written by Isaiah Richard
2021 TECHTIMES.com All rights reserved. Do not reproduce without permission.
See original here:
Twitter Bans Wordlinator, A Bot that Spoils the Wordle Game in the Social Media - Tech Times
Posted in Politically Incorrect
Comments Off on Twitter Bans Wordlinator, A Bot that Spoils the Wordle Game in the Social Media – Tech Times
Inside the Beltway: Neither U.S. or Russia would come out winner in Ukraine conflict: poll – Washington Times
Posted: at 12:10 am
NEWS AND OPINION:
Press coverage is brimming with alarming reports about a possible conflict between the U.S. and Russia over the destiny of Ukraine. Many of these reports stress that U.S. troops have been put on high alert.
What does the public think?
Almost half of Americans 47% expect that Russia will indeed invade Ukraine according to a Daily Agenda YouGov poll of 4,428 U.S. adults conducted on Monday which revealed some unsettling sentiments among the respondents.
If the conflict were to escalate to a war between the United States and Russia, few Americans believe that either side would emerge victorious, noted an analysis of the findings.
And the numbers: 41% of U.S. adults overall agreed that neither side would win. That finding includes 41% of Republicans, 50% of independents and 35% of Democrats.
Another 26% said the U.S. would emerge the victor an opinion shared by 29% of Republicans, 21% of independents and 32% of Democrats.
The survey also found that 10% felt that the Russians would win the conflict. Ten percent of Republicans, 11% of independents and 7% of Democrats agreed.
A significant 24% simply were not sure who would be victorious. Twenty percent of Republicans, 18% of independents and 26% of Democrats agreed with that.
Does the U.S. have the obligation to even enter into this confrontation?
Americans are split on whether the United States does (35%) or does not (33%) have a responsibility to protect Ukraine. Democrats (44%) are somewhat more likely than Republicans (36%) and independents (31%) to say that protecting Ukraine is the United States responsibility, the poll analysis reported.
A STUDENTS STARK TRUTH
Justo Antonio Triana is a Cuban-born student who has been in the U.S. since 2019 with his family only to discover that many Americans have a distorted view of his birthplace. That view is idealistic, he said, and has been shaped and defined by persistent left-leaning thinkers. To counter that view can be a challenge.
But its not easy to speak out against the leftist narrative. Today the mere fact of repeating progressive slogans gives you a kind of moral superiority; and instead, citing statistics condemns you to always be stigmatized as politically incorrect, Mr. Triana wrote in an essay for The College Fix, a news organization.
Sadly, its all about whats fashionable. The left has been winning the culture war, and has dictated that the cool thing to do now is to be woke. At the same time, for woke Americans it is cool to disrespect everything that the United States stands for, because for them the United States itself is nothing more than a symbol of racism and oppression that must be destroyed in the name of social justice only to later become a communist dystopian hell, Mr. Triana said.
Meanwhile, every time my Cuban friends desperate to get off the island but without the means to do so have asked me about the political situation in the United States, Ive had to tell them: Most young Americans that Ive met sympathize with socialism, and are pushing for policies that will hurt them in the long run. Then everyone responds in disbelief, and are worried, and sometimes even desperate, asking: And where will we go if the United States turns socialist? Mr. Triana noted.
NETWORKS MUFFLE BIDENS GAFFE
During a White House press conference on Monday, Fox News reporter Peter Doocy posed a last-minute question on inflation to President Biden who responded by calling Mr. Doocy a stupid son of a b. His oath was heard by one and all via a nearby microphone.
The major broadcast networks ABC, CBS, NBC went into full protection mode and downplayed Mr. Bidens oath according to a study of the coverage.
All three networks on Monday night and Tuesday morning offered sympathy for Joe Biden, wrote Scott Whitlock, an analyst for NewsBusters.org, a conservative press watchdog that monitored the follow-up coverage.
Its not easy being president, noted CBS Mornings co-host Tony Dokoupil.
The president was clearly frustrated he was peppered with questions about Ukraine at an economic event, said ABCs White House correspondent Mary Bruce in her review.
NBCs Kelly ODonnell also said the presidents gaffe was a result of frustration.
As Bidens gaffes and hot mic moments pile up, look for the networks to continue to argue for understanding and empathy towards our frustrated and sometimes bewildered president, Mr. Whitlock predicted.
The three networks did not offer much in-depth coverage either.
On Monday night and Tuesday morning, ABC allowed the least coverage on the gaffe. Just 53 seconds on Tuesday morning and nothing on Monday night. CBS came in second with 17 seconds on the CBS Evening News and 51 seconds on CBS Mornings (a total of 68 seconds.) NBC managed 45 seconds on Tuesday morning and 50 seconds on Mondays Nightly News a total of 95 seconds, Mr. Whitlock wrote.
FOXIFIED
During the week of Jan. 17-23, Fox News was the leading network across the entire cable realm, besting both news and non-news competition and drawing 2.4 million primetime viewers according to Nielsen Media Research. Fox News, in fact, aired 76 of the top 100 cable telecasts.
Among the standouts: Coverage of President Bidens big press conference was the biggest draw of the week, earning 4.2 million viewers. The Five was in second place with 3.7 million viewers, followed by Tucker Carlson Tonight (3.4 million) and Hannity (3.2 million). And one more: Fox & Friends which airs weekday mornings brought in 1.4 million viewers. In contrast, CNNs New Day attracted an audience of 354,000 viewers while MSNBCs Morning Joe drew 723,000.
POLL DU JOUR
77% of likely U.S. voters worry that microchip implants placed in human brains will be used to usher in a never-before-seen level of totalitarian control.
67% would prefer not to experience any merge with artificial intelligence.
56% fear the implants will destroy social fabric.
23% say the implants are ingenious and want to participate in such an activity.
18% say use of the implants would bring about new heights of prosperity.
Source: A John Zogby Strategies poll of 777 likely U.S. voters conducted Dec. 17, 2021, and released Monday.
Helpful information to jharper@washingtontimes.com.
See the rest here:
Inside the Beltway: Neither U.S. or Russia would come out winner in Ukraine conflict: poll - Washington Times
Posted in Politically Incorrect
Comments Off on Inside the Beltway: Neither U.S. or Russia would come out winner in Ukraine conflict: poll – Washington Times
Vote of the Week: Is Peanuts Still Worth Celebrating? – Theme Park Insider
Posted: at 12:10 am
January 22, 2022, 2:49 PM The Peanuts Celebration returns today to Knott's Berry Farm. But is Peanuts still an entertainment franchise worth celebrating?
Knott's annual Peanuts Celebration runs through March 6, giving Charlie Brown, Snoopy and the rest of the Peanuts characters more than a month in the park's spotlight. The Calico Mine Stage this year offers a new game-show-themed musical called It's Your Life, Charlie Brown, while fans can learn how to draw the Peanuts characters in the Bird Cage Theatre's Peanuts Sketch School. Franklin and Linus host the Peanuts Cowboy Jamboree at Calico Park. Knott's is rolling out new Peanuts-inspired food items for sale throughout the park, and new-to-the-park character Marcie joins the Peanuts meet-and-greet lineup.
But how many Knott's Berry Farm visitors know Peanuts as anything other than the theme for the park's Camp Snoopy children's area?
Half a century ago, Peanuts was bigger than Disney. Charles Schulz' creation anchored the comics pages of every major newspaper in America - back when pretty much every household subscribed to the local paper. The Charlie Brown Christmas, Halloween and Thanksgiving specials were must-watch television every year. Millions of American children went to school carrying Peanuts-themed lunch boxes. Peanuts characters hawked everything from their parents' life insurance to the Dolly Madison snack cakes in those lunch boxes. The Apollo 10 mission to the Moon named its lunar and command modules after Snoopy and Charlie Brown.
And, like countless other GenX kids, a Snoopy plush doll was my most prized possession and companion for years after I got it on Christmas morning.
So what happened? Why didn't Peanuts continue to grow and dominate family entertainment in the United States and abroad, the way that Disney ultimately managed to do?
A clue to that answer lies in the farewell letter that Schulz wrote to fans in Peanuts' final Sunday comic strip, which was drawn weeks in advance but ran the day after Schulz's death in February 2000:
"Unfortunately, I am no longer able to maintain the schedule demanded by a daily comic strip. My family does not wish 'Peanuts' to be continued by anyone else, therefore I am announcing my retirement."
Unlike Schulz, Walt Disney built his business to be done by others. Yes, Walt put his name on everything, but even the first Mickey Mouse cartoons were as much the work of Ub Iwerks as Walt himself.
Walt Disney built an entertainment company. Charles Schulz drew a comic strip. Ultimately, that difference explains why Peanuts failed to thrive in Schulz' later years and after his death, while The Walt Disney Company eventually grew into the most dominant entertainment brand in the world.
Yes, Schulz oversaw a multi-billion-dollar business, like Walt did. But Schulz did not branch out and create other franchises beyond Charlie Brown and company. When Schulz sold the rights to Peanuts, they did not go to a movie studio with the ability to grow the franchise across multiple media. Instead, they went to a newspaper company. (Full disclosure: I worked for that newspaper company - E.W. Scripps - for several years.)
One great deal that Charles and Schulz family made, however, was with Knott's Berry Farm. In 1983, they licensed the Peanuts characters to the park for its Camp Snoopy - a trailblazing children's area that continues to delight many young fans who have no clue what a "newspaper comic strip" might be. Even if Peanuts hasn't kept up with other animation franchises in film and television, Peanuts continues to resonate with many fans as a theme park IP. Knott's Peanuts Celebration provides an opportunity for the franchise's Boomer, GenX and elder Millennial fans to reconnection with Snoopy, Charlie Brown and the rest, even if they've long passed the age when they - or their children - would spend time in Camp Snoopy.
IP can help give a theme park attraction a head start in resonating with guests. But whether you come to an attraction knowing its backstory or not, that attraction must deliver something special to its guests to succeed. Knott's often leans on live entertainment, and the Peanuts Celebration gives Knott's talent another opportunity to show off for park audiences. The shows are cute and charming, the characters engaging, and there's plenty on the celebration menus for a variety of tastes.
So, ultimately, this celebration might not need Peanuts as much as Peanuts needs a celebration like this.
Knott's Peanuts Celebration runs daily through March 6. For discounted tickets to Knott's Berry Farm, please visit our travel partner's Knott's Berry Farm tickets page.
* * * We wanted you to read this article before we make our newsletter pitch, unlike so many other websites. If you appreciate that -and our approach to covering theme park, travel, and entertainment news -please sign up for our free, three-times-a-week email newsletter. Thank you.
Read the original:
Vote of the Week: Is Peanuts Still Worth Celebrating? - Theme Park Insider
Posted in Politically Incorrect
Comments Off on Vote of the Week: Is Peanuts Still Worth Celebrating? – Theme Park Insider
UDF leaders petition Governor on Lok Ayukta ordinance; read full text of their letter – Mathrubhumi English
Posted: at 12:10 am
Thiruvananthapuram: UDF leaders on Wednesday visited Governor Arif Mohammad Khan and handed over a petition seeking him to refrain from signing the ordinance which curtails the powers of Lok Ayukta.
The petition noted that the new set of amendments is frivolous, politically driven and in stark contravention to the established laws of the country.
Opposition leader VD Satheesan was accompanied by former CM Oommen Chandy, MLA Ramesh Chennithala and leaders of various parties in the front.
Here is the complete copy of the petition submitted by Congress leadership to the Governor:
This letter is in continuation to my earlier letter dated 25-01-2022 requesting your good self to abstain from giving your assent to the Lok Ayukta ordinance.
Please note that the reasons for the proposed amendment to the Lok Ayukta Act have been revealed by the State Law Minister and other stakeholders in public. However, those justifications appear to be frivolous, politically driven, and in stark contravention of the established laws in this Country.
The Government has cited the Kerala High Court's decisions as one of the reasons for amending Section 14 of the THE LOK AYUKTA ACT,1999. As per available information, the judgment in Sudha Devi Vs The District Collector(WP(C). No.41335 of 2016) and The Kerala State Cooperative Vs Kerala Lok Ayukta (WP(C). No.23431 of 2016) have been cited by the Government. On perusal of these judicial decisions, it is abundantly clear that the scope of Section 12(1) of THE LOK AYUKTA ACT, 1999, rather than Section 14, was subjected to judicial scrutiny in these cases. The Court has rightly pointed out that the Lok Ayukta has only recommendatory jurisdiction as per Section 12(1), which is exactly what is mentioned in the Act. The Courts decisions in these aforesaid cases are just literal interpretations of Section 12(1) of the Act, which talks about reports of Lok Ayukta and states that the Lok Ayukta shall by a report in writing recommend to the competent authority for taking appropriate decisions.
Kindly note that in the 22 year-long histories of the Lok Ayukta Act, only one decision was pronounced by Lok Ayukta invoking Section 14 of the Act. The decision was against former Minister Sri K.T. Jaleel, with the Lok Ayukta finding him guilty of nepotism and abuse of office to obtain a favour for a relative. The Kerala High Court and Supreme Court upheld the Lok Ayutka decision, demonstrating that Section 14 is in accordance with the Indian Constitution. Cases against the incumbent Higher Education Minister and the Chief Minister pending before the Lok Ayukta are to make a declaration under sec: 14 of the Act as in the case of Sri.K.T.Jaleel.
It is in fact shocking to learn that the verdicts of the High Court have been misconstrued in order to deceive the public and push anti-people legislation.
Another argument advanced by the government to justify the proposed amendment to Section 14 is that it violates Article 164 of the Indian Constitution. Article 164 discusses the appointment of the Chief Minister and other ministers, and how they hold office at the Governor's pleasure. This does not mean that the Chief Minister or other ministers can only be removed by the Governor. Many times, the Judiciary has ordered public servants to vacate their positions in quo warranto and other petitions. In fact, Section 8 of the Representation of the People Act, 1951, disqualifies a person convicted of any offence and sentenced to imprisonment for not less than two years from continuing in office. It would be absurd for the government to argue that the Apex court, High Court or a statute passed by the Legislature cannot order a public servant found to have committed a grave offence to vacate their positions.
Above all, the Indian Constitution has given the judiciary the power to validate the constitutionality of laws passed by the legislature under Articles 32, and 226. In fact, the legal principle of presumption of constitutionality requires the judge to assume that Acts passed by the legislature are constitutional unless they are found unconstitutional. Please note that no constitutional court has ever declared the impugned section unconstitutional in its 22-year history. In reality, the Supreme Court supported the Lok Ayukta's decision in the K.T.Jaleel case, demonstrating the Section's constitutional legitimacy.
However, in this ordinance, the executive is openly proclaiming a statute that has been in effect for 22 years to be unconstitutional and is proposing an ordinance to change the provision. This is ultra vires and goes against the fundamental tenets of the Indian constitution.
These facts demonstrate that the claim of unconstitutionality is baseless and founded on incorrect premises.
Another odd justification advanced by the Law Minister in defence of the proposed legislation is that the current Act lacks an appeal provision. There are various laws in this country that do not provide for appeals. Lok Adalat formed under Legal Services Authorities Act, is one example. The lack of an appeal clause in the original legislation can be justified by the fact that the Lok Ayukta would be a Supreme Court Judge or a retired High Court Chief Justice. Kindly note that the decisions of the Lok Ayukta can be challenged in the High Court as per Article 226 and Article 227.
In fact, the opposition will enthusiastically support measures amending the Said Act to include an appeal provision entrusting with a Division Bench of the High Court.
It's ironic that the proposed amendment, which purports to correct a violation of natural justice, actually contradicts the natural justice principle's basic premises.
The proposed amendment to Section 14 of the ordinance gives the Governor, the Chief Minister, or the government in their capacity as the competent authority to either reject or accept the decision of the Lok Ayukta after hearing both the parties. It is strange how an executive could serve as an appeal authority on a decision pronounced by a judicial or quasi-judicial forum consisting of former Supreme Court judge or Chief Justice of the High Court.
According to the natural justice maxim "Nemo Judex in causa sua," no one should be a judge in his or her own cause. After the proposed amendment, the case against the Chief Minister would be decided by the Governor, while the case against the Ministers would be decided by the Chief Minister. According to Article 163, the Governor has to exercise his functions at the aid and advise the council of Ministers with the Chief Minister at the head. As a result, the Chief Minister has a substantial say in the cases brought against him. This is an outright denial of natural justice.
Please take note that the contested provision in the ordinance was part of the original bill of the THE LOK AYUKTA ACT, 1999 when it was first introduced in the legislative assembly. However, due to widespread objections from members of both the opposition and the ruling party during the debate on February 22, 1999, this was withdrawn. In other words, this government is pushing through legislation that the Kerala Legislative Assembly debated and rejected.
The hastiness in bringing this ordinance is dubious and has put the probity of the government under scanner. As per Article 213, which talks about ordinances, compelling circumstances which render it necessary to take immediate action should exist as a prerequisite for promulgating an ordinance. With the legislative assembly session slated for next month, there seems to be no compelling reason to change the law, which has been in existence for over 22 years. The only immediate reason that could be perceived is that the Lok Ayukta is about to take up cases against the Chief Minister in relief fund misappropriation and the Higher Education Minister in the university issue. It should be understood that the government is expecting an unfavourable verdict in these cases and this ordinance is a shield to guard against any unsavoury decisions from the Lok Ayukta.
Moreover, the proposed amendment would serve as a catalyst for rampant corruption and nepotism.
In these compelling circumstances, taking into consideration the interest of the State and public at large, I request your good self to abstain from providing your assent to the Kerala Lok Ayukta (amendment) ordinance 2021.
-VD Satheesan, Chairman, UDF.
View original post here:
UDF leaders petition Governor on Lok Ayukta ordinance; read full text of their letter - Mathrubhumi English
Posted in Politically Incorrect
Comments Off on UDF leaders petition Governor on Lok Ayukta ordinance; read full text of their letter – Mathrubhumi English
The best of Manfred Thierry Mugler’s theatrical, otherworldly fashion – i-D
Posted: at 12:09 am
Yesterday, we learned the sad news that legendary designer Manfred Thierry Mugler had passed away at the age of 73. The king of otherworldly fashion, his eponymous label pushed the boundaries of what a fashion show could be, turning them into over-the-top moments of theatre.
However, it was dance, not fashion that was the designers first passion. Born in Strasbourg, France, in 1948, he performed as a dancer with the Rhine Opera Ballet from 1965 to 1966 before moving to Paris, where he became a window dresser at fashion boutique Gudule.
From there, he began freelancing as an assistant designer for a number of fashion houses, before starting his own ready-to-wear line, Caf de Paris, in 1973. I never dreamed of being a fashion designer. I wanted to be a director, the designer told T Magazine in 2019. But fashion happened to be a good tool. It was a means of communicating. His debut, which featured precise, streamlined silhouettes inspired by his dance background, became the foundations of his namesake line, which was launched a year later in 1974.
At Thierry Mugler, the designer became known for his strong silhouettes power shoulders with snatched waists use of unconventional materials and unexpected inspirations like science fiction, insects, and fantastical creatures. After building an empire that included a successful series of fragrances, financial difficulties led to the designer retiring from the brand in 2003.
While his label has continued without him at the helm Casey Cadwallader is the current creative director, preceded by the likes of Nicola Formichetti and David Koma he continued to create, working on short films with Isabelle Huppert, as well as designing costumes for operas, theatre, the Cirque du Soleil, and even a Beyonc tour.
More recently, the designers recent projects included dressing Cardi B in three looks from his archive most notably the Venus sheath dress from his AW95 couture show for the 2019 Grammys, and coming out of retirement to create Kim Kardashian Wests outfit for the 2019 Met Gala. After previously declining offers from The Met and V&A, the designer collaborated with Montreals Museum of Fine Arts on a retrospective of his work, with Thierry Mugler: Couturissime later travelling to the Muse des Arts Dcoratifs in Paris (where its currently showing until the end of April).
Muglers death is another huge loss for fashion following in the wake of recent losses in the form of Andr Leon Talley and Virgil Abloh and his undeniable impact, years after he stopped designing on-schedule, will undoubtedly continue long after his death.
My work is timeless because its based on the beauty of the human body and the fascinating world we live in, he once reflected on his impact. My work pays tribute to the woman and gives her personality I give them armour.
From the beginning of his career, Muglers shows toed the line of fashion, theatre, and performance inspired by his background in dance. For the designers 10th anniversary AW84 show, Mugler took the fashion show experience to dizzying new heights. Taking over the Znith arena in Paris, the show was presented to 6000 people, marking the first time that the public had access to a show at Paris Fashion Week. The show-stopping event featured 350 models acting in short vignettes inspired by Olympian and religious motifs, before the grand finale in which a pregnant Pat Cleveland cosplaying as the Madonna in an angelic bedazzled gown and headdress was lowered from the heavens in a puff of smoke before walking the catwalk, triggering the release of thousands of rose petals. This stadium-scale style of show was later adopted by the likes of Yves Saint Laurent and Jean Paul Gaultier, and inspired a new generation of showmen like John Galliano and Alexander McQueen.
Throughout his career, Mugler teamed up with celebrities who shared his button-pushing creativity, working with names including (but not limited to) David Bowie, Grace Jones, Diana Ross, and George Michael. After coming across one of his iconic motorcycle corsets in the Metropolitan Museum Costume Institute, Beyonc tapped the designer as creative director for her 2009 I Am tour in which he designed 58 costumes for the singer alone, as well as directing segments of the show, and providing input on choreography and lighting.
Long before runway diversity was a talking point, Mugler would often feature models who didnt meet the prevailing industry standard (read: tall, white, and thin). As well as casting plus-size models like Stella Ellis and drag queens like Lipsynka, the designers shows prominently featured trans models like Connie Fleming, Teri Toye, and Roberta Close leading to them walking for the likes of Chanel and Vivienne Westwood. For the designers SS92 show, the cast of models included a mind-bending combination of the porn star Jeffrey Stryker, Deee-Lites Lady Miss Kier and Dmitry, and recently divorced Ivana Trump. It prompted acerbic critic Cathy Horyn to pen in the Washington Times: Mugler's shows have pretty much ceased to be about fashion per se. They are about the people who are in his shows socialites, peroxided Lido stars, pop singers, bouffant transvestites and in that sense they are for the people who live for fashion.
While Mugler is synonymous with iconic fashion design, he was a multi-hyphenate creative, pursuing photography after prompting from Helmut Newton. While working with the legendary photographer on the set of one of his campaigns, his uncompromising vision led Newton to tell Mugler to shoot the images himself, and he did. His photographic oeuvre is as grand as the catwalk shows he produced, filled with images shot in far-flung locales, from the salt flats of the Atacama Desert in Chile to the middle of the Sahara, or 20km into the ocean on an iceberg. In perhaps one of his most iconic images, he lensed model Claude Heidemeyer at feet-tingling heights perched atop the gargoyles of the Chrysler building. Risking his life for the shot, Mugler was balanced out of a window two floors above on a ladder, while two assistants inside held it so he wouldnt fall. See: uncompromising vision.
Thierry Mugler fashion show, Haute Couture Fall-Winter 1995-96 collection in Paris in March 1995, France. (Photo by Daniel SIMON/Gamma-Rapho via Getty Images)
In 1996, the notoriously rigid Chambre Syndicale de la Couture invited Mugler to officially show on the couture schedule, and his foray into it motivated him to explore and innovate what fashion on this level could look like. Already famous for using unconventional materials like latex, rubber tyres, and car parts for his AW89 motorcycle corsets, he collaborated once again with Jean-Jacques Urcun to create a look that was six months in the making. Swaddled underneath a grand purple overcoat, the model disrobed to reveal a shining chrome suit of armour, a futuristic look that leaned into the designers transhuman interests while remaining femininely beautiful and undeniably chic.
Photo by Pierre Vauthey/Sygma/Sygma via Getty Images
The instantly recognisable Chimre gown from the designers AW97 haute couture collection is arguably the crown jewel of Muglers design legacy. Transforming model Adriana Karembeu into an otherworldly fish-bird creature complete with piercing eyes, reptilian and yellow the dress was a labour of love, created in collaboration with artist Jean-Jacques Urcun and renowned corset-maker Mr Pearl. Unlike anything seen before it (or since), the gold armour-like corset explodes into a kaleidoscope of sparkling crystals, hand-painted scales, feathers and horsehair. It unsurprisingly required countless hours of work in the atelier to be constructed, with a team of 20 people working around the clock for six weeks to bring the vision to life.
One of Muglers biggest bonanzas, the AW95 couture show, was an hour-long spectacle in celebration of the 20th anniversary of the house and featured supers including Naomi Campbell, Linda Evangelista, Claudia Schiffer and Kate Moss, as well as Jerry Hall, actress Tippi Hedren, and James Brown, who performed. The collection featured some of Muglers most celebrated designs such asVenus, the silver fembot, the gaggle of latex ladies, and Nadja Auermann in the iconic gold, crystallised corset later given a new lease of life in Beyoncs Sweet Dreams music video.
Photo by Karwai Tang/Getty Images
After retiring from fashion in 2003, in 2019 Mugler made his red-carpet return, designing a look for Kim Kardashians appearance atthe Met Gala Camp: Notes on Fashion, the theme that year working with longtime collaborator Mr Pearl over a period of eight months. Inspired by Sophia Lorens sponge-diving character Phaedra in the 1957 film Boy on a Dolphin, the nude latex dress glistened with sequins and dripping crystals. He envisioned me as this California girl stepping out of the ocean, wet, dripping, Kim said on the Met red carpet, about her look before adding: Manfred Thierry Mugler is the definition of camp.
Follow i-D onInstagramandTikTokfor more on fashion
Go here to see the original:
The best of Manfred Thierry Mugler's theatrical, otherworldly fashion - i-D
Posted in Transhuman News
Comments Off on The best of Manfred Thierry Mugler’s theatrical, otherworldly fashion – i-D
Silencing a faulty gene may uncover clues to rare forms of ALS – National Institutes of Health
Posted: January 27, 2022 at 11:55 pm
News Release
Monday, January 24, 2022
NIH-funded preclinical study identifies potential therapeutic approach to treat ALS.
Using an experimental drug, researchers were able to suppress a mutated amyotrophic lateral sclerosis (ALS) gene. Studies in mice demonstrate that the therapy could show promise in treating rare, aggressive forms of ALS caused by mutations in the fused in sarcoma (FUS) gene. The study, published in Nature Medicine, was funded in part by the National Institute for Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health.
The study models how promising gene-targeting therapies can move expeditiously from pre-clinical development to clinical testing, said Amelie Gubitz, Ph.D., program director at NINDS. There is a desperate need for innovative approaches to treating ALS.
ALS, also known as Lou Gehrigs disease, is a fatal neurological disorder that causes the degeneration of motor neurons in the brain and spinal cord. People with ALS rapidly lose muscle strength and eventually their ability to move, swallow, and breathe. Most cases of ALS are sporadic, but at least 10% of cases are familial, or due to mutations in various genes. Mutations in the gene FUS cause severe forms of ALS, referred to as FUS-ALS, including a rare type that begins in adolescence or young adulthood.
In the study, Neil Shneider, M.D., Ph.D., the Claire Tow Associate Professor of Motor Neuron Disorders and Director of the Eleanor and Lou Gehrig ALS Center at Columbia University, New York City, and his team delayed the onset of motor neuron degeneration in mice by using an antisense oligonucleotide drug designed to silence FUS by blocking cells from making specific proteins. Following encouraging results, they administered the drug to a patient with ALS.
Compared to normal mice, mice with a mutated FUS gene had higher levels of insoluble FUS and other ALS-related proteins in their brains and spinal cords. Mice with higher doses of mutant FUS in motor neurons experienced rapid neurodegeneration that began early in life, much like FUS-ALS patients.
The study establishes a mouse model that is highly disease-relevant, said Dr. Shneider. In mice, we found that FUS toxicity was due to a gain of function and was dose-dependent, suggesting that we could treat FUS-ALS by silencing the FUS gene.
In 2019 Dr. Shneider met an individual with ALS in search of therapies that may help her disease. Inspired by her story, Dr. Shneider teamed up with a pharmaceutical company to develop a personalized therapy designed to target the FUS mutation.
In mice, injecting a single dose of the drug into the ventricles, fluid-filled spaces surrounding the brain, delayed the onset of inflammation and motor neuron degeneration by six months. The drug also knocked down levels of FUS by 50% to 80% in the brain and spinal cord. Following drug administration, insoluble forms of other ALS-associated proteins were also cleared.
Under a compassionate use protocol reviewed by the U.S. Food and Drug Administration, Dr. Shneider administered the drug to the patient it had been designed for. The patient received repeated infusions of the drug into her spinal canal for 10 months. During the treatment, the patients rate of motor function deterioration slowed. The patient tolerated the treatment well and there were no medically adverse effects.
The study is an example of a precision medicine, bench-to-bedside effort, said Dr. Shneider. We began with the mouse model to establish a rationale for the drug, conducted efficacy studies in the mouse, moved the drug into a human, and collected valuable data that was ultimately used to support a larger Phase 3 clinical trial.
Treatment began more than six months after clinical onset, by which time the disease had already significantly advanced. As is typical with juvenile-onset FUS-ALS, the disease progressed rapidly, and the patient died from complications of the disease.
By studying the patients brain and spinal cord tissue, researchers found that the drug silenced FUS throughout the nervous system and reversed the toxic nature of FUS and other disease-related proteins. Compared to tissue from untreated FUS-ALS patients and healthy controls, FUS protein aggregatesa pathological hallmark of this form of ALSwere sparse, suggesting that they may have been cleared by the drug. Tissue samples were provided by the New York Brain Bank of Columbia University.
The protein made from the FUS gene has been shown to be important for various cellular processes. Prior studies in mice suggest that FUS mutations result in the production of an abnormal protein that forms clumps, or aggregates, leading to motor neuron damage. By targeting the faulty gene in a way that suppresses toxic FUS activity, gene silencing products like the antisense oligonucleotide drug could potentially reduce or prevent disease progression.
The results were used to support a clinical trial testing the drug in patients with FUS-ALS (NCT04768972).
This study was supported by grants from the NIH (NS106236), Nancy Perlman, Tom Klingenstein, and the Judith and Jean Pape Adams Charitable Foundation.
NINDSis the nations leading funder of research on the brain and nervous system.The mission of NINDS is to seek fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease.
About the National Institutes of Health (NIH):NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.
NIHTurning Discovery Into Health
Korobeynikov, V.A., et al. Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis. Nature Medicine, January 24, 2022. DOI: 10.1038/s41591-021-01615-z
###
Link:
Silencing a faulty gene may uncover clues to rare forms of ALS - National Institutes of Health
Posted in Gene Medicine
Comments Off on Silencing a faulty gene may uncover clues to rare forms of ALS – National Institutes of Health
Their DNA Hides a Warning, but They Dont Want to Know What It Says – The New York Times
Posted: at 11:55 pm
I was like, wait a minute. Where is this information going? How will it be utilized? she later asked. I dont know if there are any implications for life and health insurance for me or my family, but why risk it?
What should happen when researchers, while sequencing a participants DNA as part of a large study, discover gene variants that increase the risk for conditions that might be prevented with medical treatment or surveillance? Some researchers believe they have an obligation to find the participants often years after they provided a DNA sample contact them, and tell them what they have found. But, some research subjects, like Ms. Konstadt, feel they have a right not to know. Is it ethical for doctors to let them insist they can opt out of learning more without first knowing the particular risk they are facing?
For Dr. Robert Green, an investigator for the biobank with Ms. Konstadts DNA, the Mass General Brigham Biobank, and author of a recent paper about its policies, the answers are clear. The consent form for the biobank tells participants that if the researchers find a worrisome variant, and if there is an intervention that can reduce risk, the participants will be contacted. There will be seven attempts to reach participants calls and letters before the team gives up.
We are offering the information, not forcing participants to accept it, said Dr. Green, who is also a geneticist and professor of medicine at Harvard. If you dont answer the phone or decide when offered that you dont want to hear anything more, or even hang up on us when we call, then thats your choice.
Dr. Green and his colleagues point out that the possibility of being contacted was in the consent form:
While you should not expect to receive any results from your participation in this research, if experts from the Biobank decide that research results from your sample are of high medical importance, we will attempt to contact you. In some situations, follow up testing might be needed in a certified clinical lab. You and your medical insurer may be responsible for the costs of these tests and any follow up care, including deductibles and co-payments.
But some, like Ms. Konstadt, did not notice that clause when signing the form.
Out of more than 36,000 participants, whose DNA its researchers analyzed, the Mass General Brigham Biobank found 425 with worrisome gene variants whose effects could be ameliorated by depending on the genes enhanced cancer surveillance or aggressive medical treatments to lower cholesterol levels, for example.
See the original post here:
Their DNA Hides a Warning, but They Dont Want to Know What It Says - The New York Times
Posted in Gene Medicine
Comments Off on Their DNA Hides a Warning, but They Dont Want to Know What It Says – The New York Times
BridgeBio Pharma Announces Dosing of First Patient in Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH) -…
Posted: at 11:55 pm
-If successful, BridgeBios investigational gene therapy BBP-631 would be the first therapy for CAH to restore the bodys hormone and steroid balance by enabling people with CAH to make their own cortisol and aldosterone
-Initial Phase 1/2 data readout anticipated in the second half of 2022
-BridgeBios gene therapy portfolio also includes a clinical stage program for Canavan disease and preclinical programs for classic galactosemia, TMC1 hearing loss, tuberous sclerosis types 1 and 2, cystinuria and a genetic dilated cardiomyopathy
PALO ALTO, Calif., Jan. 27, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that the first patient has been dosed in ADventure, its Phase 1/2 clinical trial of BBP-631, an investigational adeno-associated virus (AAV) 5 gene therapy for the treatment of classic congenital adrenal hyperplasia (CAH). CAH is one of the most prevalent genetic diseases, with more than 75,000 cases estimated in the United States and European Union.
Dosing the first patient in our CAH trial is a landmark milestone and we are grateful for the support from the medical and patient communities who helped us reach this moment. For more than 50 years people living with CAH have had the same limited standard of care lifelong daily steroid replacement treatment. Our investigational gene therapy offers patients a potential single-dose intervention designed to restore their bodys hormone and steroid balance by making their own cortisol and aldosterone, said Eric David, M.D., J.D., CEO at BridgeBio Gene Therapy. This is the second gene therapy trial we have initiated in less than four months, and we are excited to advance this trial and our other gene therapy programs in the hope of improving patients lives.
Adults, children and families affected by CAH experience the daily burden of the disease and often, unfortunately, the side effects and morbidities associated with the current treatment regimens. As an endocrinologist, its incredibly exciting to reimagine a new approach to treating this disease, added Adam Shaywitz, M.D., Ph.D., chief medical officer at BridgeBio Gene Therapy. Adrenas Therapeutics, the affiliate company of BridgeBio focused on developing BBP-631 for CAH, is part of BridgeBio Gene Therapys portfolio.
The Phase 1/2 open-label study is designed to evaluate the safety, tolerability and pharmacodynamic activity of the companys AAV5 gene therapy, BBP-631, in adults with classic CAH. In the initial dose-finding phase of the study, each subject will receive a single intravenous (IV) infusion. The primary outcomes of the study are safety, as well as change from baseline in endogenous cortisol levels which BBP-631 has the unique potential to restore. Change from baseline in steroid biomarkers for hydroxyprogesterone (17-OHP) levels and androstenedione (A4) levels will also be measured. Preclinical proof-of-concept data have shown the approach provides efficient and persistent delivery of functional 21-hydroxylase (21-OH) enzyme to the adrenal gland.
We are honored to be the first site to administer gene therapy in a patient with CAH as it is a potential game-changing treatment option that targets the disease at its source, said Kyriakie Sarafoglou, M.D., associate professor and director of the Center for Congenital Adrenal Hyperplasia at the University of Minnesota. We are eager to see whethergene therapy can restore endogenous cortisol production, and also look forward to exploring its effect on thephysiological mechanisms that regulate the hypothalamic-pituitary-adrenal axis including circadian and ultradian hormonal profiles.
BridgeBios investigational AAV5 gene therapy for CAH is one of the Companys 14 programs that are in the clinic or commercial setting for patients living with genetic diseases and cancers. Initial Phase 1/2 data readouts of the Companys AAV5 gene therapy for CAH and the Companys AAV9 gene therapy for Canavan disease are expected in the second half of 2022.
For more information about the ADventuretrial, visit ClinicalTrials.gov (NCT04783181).
About BBP-631BBP-631 is an AAV5 gene therapy developed to treat CAH due to 21-hydroxylase deficiency at its source. BBP-631 is designed to deliver a functional copy of the 21-hydroxylase gene and has been shown through multiple preclinical studies to result in efficient and persistent delivery to the adrenal gland, where hormones are naturally made. If successful, BBP-631 may restore the bodys hormone and steroid balance by enabling people with CAH to naturally make their own cortisol and aldosterone. It could also allow for people with CAH to eliminate or significantly reduce their daily glucocorticoid or mineralocorticoid doses, which is the current standard of care for patients.
About Congenital Adrenal Hyperplasia (CAH)Affecting approximately 75,000 people in the United States and European Union, CAH is a group of genetic disorders that affect the adrenal glands, which is caused by a mutation in the gene encoding for 21-hydroxylase, an enzyme essential for making the hormones cortisol and aldosterone which are critical for various physiologic functions. Cortisol is necessary for the body to respond to injury, stress or illness, and aldosterone is required to maintain proper blood pressure and sodium levels. Unable to produce cortisol and aldosterone, people with classic CAH cannot mount the healthy physiological response to stressors, such as illnesses, that allows their heart, lungs, kidneys and other organs to compensate for the stress, which can be life-threatening. These adrenal crises can be particularly dangerous for young children.
About BridgeBio Pharma, Inc.BridgeBio Pharma, Inc. (BridgeBio) is a commercial-stage biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. BridgeBios pipeline of over 30 development programs ranges from early science to advanced clinical trials and its commercial organization is focused on delivering the companys first two approved therapies. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn and Twitter.
BridgeBio Pharma, Inc. Forward-Looking StatementsThis press release contains forward-looking statements. Statements we make in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the Securities Act), and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), which are usually identified by the use of words such as anticipates, believes, estimates, expects, intends, may, plans, projects, seeks, should, will, and variations of such words or similar expressions.We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements, including statements relating to the timing and success of BridgeBios Phase 1/2 clinical trial of BBP-631 for the treatment of CAH, expectations, plans and prospects regarding BridgeBios regulatory approval process for BBP-631, the ability of BBP-631 to treat CAH in humans, and the timing and success of initial top-line Phase 1/2 date of BBP-631, reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved.Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, BridgeBios ability to continue and complete its Phase 1/2 clinical trial of BBP-631 for the treatment of CAH, past data from preclinical studies not being indicative of future data from clinical trials, BridgeBios ability to advance BBP-631 in clinical development according to its plans, the ability of BBP-631 to treat CAH, the ability of BBP-631 to retain Fast Track Designation, Rare Pediatric Drug Designation, and Orphan Drug Designation from the U.S. Food and Drug Administration and Orphan Drug Designation from the European Medicines Agency, risks inherent in developing therapeutic products, the success, cost, and timing of the Companys product candidate research and development activities and ongoing and planned preclinical studies and clinical trials, the success and timing of preclinical study and clinical trial results, the success of its clinical trial designs, the fact that successful preliminary preclinical study or clinical trial results may not result in future clinical trial successes and/or product approvals, trends in the industry, the legal and regulatory framework for the industry, the success of current and future agreements with third parties in connection with the development or commercialization of the Companys product candidates and FDA-approved products, the size and growth potential of the market for the Companys product candidates and FDA-approved products, the Companys ability to access additional funding upon achievement of portfolio milestones, the accuracy of the Companys estimates regarding expenses, future revenue, future expenditures and needs for and ability to obtain additional financing, the Companys ability to be a sustainable genetic medicine innovation engine and to build the next great genetic medicine company, the Companys ability to obtain and maintain intellectual property protection for its product candidates and approved products, the competitive environment and clinical and therapeutic potential of the Companys product candidates and FDA-approved products, the Companys international expansion plans, and potential adverse impacts due to the global COVID-19 pandemic such as delays in clinical trials, preclinical work, overall operations, regulatory review, manufacturing and supply chain interruptions, adverse effects on healthcare systems and disruption of the global economy; as well as those set forth in the Risk Factors section of BridgeBios most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) and in subsequent SEC filings, which are available on the SECs website atwww.sec.gov.Moreover, BridgeBio operates in a very competitive and rapidly changing environment in which new risks emerge from time to time. Except as required by applicable law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
BridgeBio Media Contact:Grace RauhGrace.rauh@bridgebio.com(917) 232-5478
BridgeBio Investor Contact:Katherine Yaukatherine.yau@bridgebio.com(516) 554-5989
Posted in Gene Medicine
Comments Off on BridgeBio Pharma Announces Dosing of First Patient in Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH) -…